Ayr Wellness (AYR-A) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $114.3 million, down 2.5% sequentially and flat year-over-year, missing guidance due to price compression and macro headwinds in key markets.

• Adjusted EBITDA improved 1.6% sequentially to $26.1 million, with margin rising 100 basis points to 22.9% due to gross margin expansion and operating efficiencies.

• Leadership changes included the appointment of an Interim CEO, new Chairman, and restructuring of the senior management team to enhance accountability and execution.

• Expansion efforts are focused on Florida, Ohio, Virginia, and Pennsylvania, with new cultivation and retail facilities coming online.

Financial highlights

• Q3 sales were $114.3 million, down 2.5% from the prior quarter and flat year-over-year.

• Gross profit was $43 million, down 9% sequentially and 11% year-over-year.

• Adjusted gross margin was 52.8%, up 100 basis points from the prior quarter.

• Loss from continuing operations was $17.4 million, an increase of $9.8 million from the prior quarter.

• Net loss attributable was $50.6 million, or $0.44 per share (basic and diluted) for Q3 2024.

• Cash, cash equivalents, and restricted cash at quarter-end was $51 million, up $3.1 million sequentially.

Outlook and guidance

• Q4 2024 revenue and adjusted EBITDA are expected to be in line with Q3, reflecting continued consumer and competitive pressures.

• Positive cash flow from operations is expected for the full year 2024.

• CapEx for 2025 is projected to be 25%-50% lower than 2024, with a focus on retail expansion in Ohio and Virginia.